The Primacy of Public Health Considerations in Defining Poor Quality Medicines

Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.

Detalles Bibliográficos
Autores principales: Newton, Paul N., Amin, Abdinasir A., Bird, Chris, Passmore, Phillip, Dukes, Graham, Tomson, Göran, Simons, Bright, Bate, Roger, Guerin, Philippe J., White, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Essay
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232210/
https://www.ncbi.nlm.nih.gov/pubmed/22162953
http://dx.doi.org/10.1371/journal.pmed.1001139
Descripción
Sumario:Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.

Ejemplares similares